Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Withdrawn × Lymphatic Metastasis × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Completed 4 Recruiting 2 Withdrawn 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 93 Carcinoma, Non-Small-Cell Lung 82 Multiple Myeloma 57 Prostatic Neoplasms 54 Neoplasm Metastasis 54 Colorectal Neoplasms 53 Neoplasms 49 Recurrence 36 Leukemia, Myeloid, Acute 36 Carcinoma, Hepatocellular 34 Lung Neoplasms 33 Melanoma 28 Lymphoma 28 Leukemia, Lymphocytic, Chronic, B-Cell 28 Pancreatic Neoplasms 25 Rectal Neoplasms 22 Head and Neck Neoplasms 22 Glioblastoma 22 Squamous Cell Carcinoma of Head and Neck 21 Lymphoma, Large B-Cell, Diffuse 21 Leukemia 21 Ovarian Neoplasms 20 Myelodysplastic Syndromes 18 Brain Neoplasms 18 Hematologic Neoplasms 17 Carcinoma, Renal Cell 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Colonic Neoplasms 16 Uterine Cervical Neoplasms 14 Triple Negative Breast Neoplasms 14

Interventions

Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05504642 2023-04-18

CERAD-IMMUNE

Universitätsklinikum Köln

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡